Toxicol Appl Pharmacol 261:1818 Steele ML, Fuller S, Patel M, Kersaitis C, Ooi L, Mnch G (2013) Effect of Nrf2 activators on release of glutathione, cysteinylglycine and homocysteine by human U373 astroglial cells
Food and Drug Administrations (FDA) Approved Drugs database does not include BPC-157 or any of its other names
Not for human consumption, therapeutic use, or diagnostic purposes
NADPH then "drops off" the molecules and electrons, returns to its NAD+ state, and goes back to the mitochondria for more
Common (5-15% of users): Mild injection site reactions, minor digestive changes Uncommon (1-5%): Sleep changes, temporary fatigue, mild headache Rare (under 1%): Dizziness, flushing, mood changes Very Rare: Serious adverse effects rarely reported in community use Theoretical Concerns BPC-157s ability to stimulate angiogenesis (blood vessel formation) raises theoretical questions about its use in individuals with active cancer or high cancer risk
B12 injections promote healthy cell growth, repairing damage as necessary